Target for anti-cancer and immune-enhancing
AssigneeGenome and Company
InventorsBu-Nam Jeon, Yun Yeon Kim, Suro Lee, Youn Kyung Houh, Joo-Yeon Chung, Areum Jeong, Mi Young Cha
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
Claims18
A method of treating a CNTN4-expressing cancer, comprising administering an inhibitor of CNTN4 to a subject in need thereof, wherein the CNTN4-expressing cancer is stomach cancer, lung cancer, liver cancer, colorectal cancer, colon cancer, small intestinal cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenosis, uterine cancer, cervical cancer, esophageal cancer, thyroid cancer, parathyroid cancer, renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer, leukemia, lymphoma, or fibroadenoma.
A method of immune-enhancing, comprising administering an inhibitor of CNTN4 to a subject in need thereof.
Dependencies are inferred from the claim text.